Blue dye and radioactive tracer team up to spot cancer spread
NCT ID NCT00314405
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two methods—radioactive isotope and blue dye injection—to locate sentinel lymph nodes in 100 breast cancer patients. The goal was to see if using both together improves accuracy and cost-effectiveness. Researchers compared the results and analyzed the economic impact of the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- methylene blue dye and rhenium sulfide isotope
- What this could lead to
- If successful, this could lead to a more accurate and cost-effective way to identify sentinel lymph nodes in breast cancer surgery.
- What could go wrong
- This is a small, completed study with 100 patients, so results may not apply to all breast cancer cases. The methods are already in use, so major breakthroughs are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFILTRATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Gynécologie-Obstétrique, Hôpital Civil
Strasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.